The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration

Area of Science:

• Biomedical science
• Drug development
• Metabolic research

Background:

• Precompetitive collaboration drives innovation and productivity in biomedical science.
• The Biomarkers Consortium is a public-private partnership focused on biomarker development.
• Biomarker qualification is crucial for drug development and personalized medicine.

Purpose of the Study:

• To evaluate the utility of adiponectin as a predictive biomarker.
• To assess metabolic responses to peroxisome proliferator-activated receptor (PPAR) agonists.
• To demonstrate the feasibility of cross-company precompetitive collaboration for biomarker qualification.

Main Methods:

• Utilized a public-private platform for precompetitive collaboration.
• Focused on biomarker development within the context of type 2 diabetes.
• Investigated adiponectin's role in predicting metabolic responses.

Main Results:

• Adiponectin demonstrated potential utility in predicting metabolic responses.
• The study involved individuals with type 2 diabetes.
• Successfully navigated challenges in cross-company collaboration.

Conclusions:

• Cross-company precompetitive collaboration is a feasible and robust approach for biomarker qualification.
• Adiponectin shows promise as a predictive biomarker for PPAR agonist therapy.
• The Biomarkers Consortium model facilitates significant advancements in biomarker science.